Why The UroGen Pharma (URGN) Investment Story Is Shifting As Analysts Hold Fair Value Steady [Yahoo! Finance]
Urogen Pharma (URGN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $33.00 price target on the stock.
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen Applauds BCAN's New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence [Yahoo! Finance]
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence